Immunic is trading at $14.08 (+5.15%) on broad biotech strength and a rebound from recent technical pressure.
- The stock is tracking a 2.31% rally in the broader biotech sector as risk appetite improves across the industry.
- No company-specific catalysts, earnings, or regulatory updates were identified to explain the move directly.
- The advance follows a weak two-day slide earlier in the week, suggesting the move is a technical recovery.